Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
Short bioregulator investigated in chromatin; a prostate narrative is not a validated clinical target.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context
Marketed for prostate support; not equivalent to benign-hyperplasia/prostate-cancer treatment.
Human evidence
The selected paper is human lymphocyte culture with copper/cadmium and Prostamax. It was not a urinary-symptom/prostate-disease clinical trial.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The selected paper is human lymphocyte culture with copper/cadmium and Prostamax. It was not a urinary-symptom/prostate-disease clinical trial.
The selected paper is human lymphocyte culture with copper/cadmium and Prostamax. It was not a urinary-symptom/prostate-disease clinical trial.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No human regimen/clinical interactions were verified; cell results do not justify postponing urinary-symptom assessment.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID19359734 · Cell experiment
Cultured human lymphocytes.
Metal/peptide culture.
Experimental microcalorimetry changes.
Not clinical prostate-disease evidence.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Prostamax · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID19359734
Kiladze M, Gorgoshidze M, Monaselidze J, Jokhadze T, Lezhava T.
October 16, 2026
- SEARCH-PUBMED-prostamax
PubMed/MED targeted search: TITLE_ABS:prostamax
October 16, 2026